literature

SARS_CoV_2 mutation literature information.

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.

PMID: 34688034 2021 EBioMedicine

Discussion: The least negative impact on neutralization was seen for Iota variant, which is reasonable since this isolate has very few changes in the spike protein (T95I, D253G and D614G) compared to the wild type WA1 isolate.

Evaluation of the clinical and analytical performance of the Seegene allplex SARS-CoV-2 variants I assay for the detection of variants of concern (VOC) and variants of interests (VOI).

PMID: 34628158 2021 Journal of clinical virology

Table: D253G

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.

PMID: 34549975 2021 Journal of virology

Table: D253G

Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.

PMID: 34536797 2021 Virology

Result: The same phenotype is applicable to most of its mutations, with the exception of D253G substitution in the NTD, which showed a modest ~1.2-fold decrease in binding.

Genomic mutations and changes in protein secondary structure and solvent accessibility of SARS-CoV-2 (COVID-19 virus).

PMID: 33568759 2021 Scientific reports

Table: D253G

Community-level SARS-CoV-2 sequence diversity revealed by wastewater sampling.

PMID: 34438144 2021 The Science of the total environment

Table: D253G

Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.

PMID: 34428777 2021 Nature

Method: We assayed the neutralizing activity of monoclonal antibodies, convalescent plasma and vaccinee sera against E484K, S477N and wild-type (D614G) pseudoviruses, as well as pseudovirus NYDelta5 containing all five signature mutations of B.1.526-E484K (L5F, T95I, D253G, E484K, D614G and A701V), as previously described.

Figure: a, Neutralizing activities of 12 monoclonal antibodies against pseudoviruses containing E484K alone or all five signature B.1.526 mutations (L5F, T95I, D253G,

Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York.

PMID: 34373458 2021 Nature communications

Result: Regarding four of the spike mutations prevalent in this lineage: (1) E484K is known to attenuate neutralization of multiple anti-SARS-CoV-2 antibodies, particularly those found in class 2 anti-RBD neutralizing antibodies, and is also present in variants B.1.351 and P.1/B.1.1.248, (2) D253G has been reported as an escape mutation from antibodies against the N-terminal domain, (3) S477N has been identified in several earlier lineages, is near the epitopes of multiple antibodies, and has been implicated to increase viral infectivity through enhanced interactions with ACE2, and (4) A701V sits adjacent to the S2' cleavage site of the neighboring protomer and is shared with variant B.1.351.

Figure: a Pseudovirus with sp

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.

PMID: 34311587 2021 mBio

Introduction: The D253G mutation is located in the amino-terminal supersite that serves as a binding site for neutralizing antibodies, while A701V is located adjacent to the furin processing site.

Introduction: The B.1.526 variant spike proteins contain the D614G mutation, a shared set of novel mutations (L5F, T95I, D253G, and A701V

Introduction: Two versions of B.1.526 were identified, both having the D614G and A701V mutations and, in addition, the mutations L5F, T95I, and D253G, which are not present in previously reported variants.

Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.

PMID: 34307771 2021 Virusdisease

Table: D253G

Browser Board

Co-occurred Entities

Filtrator